Ganoderma

Ganoderma: A Comprehensive Encyclopedic Reference

1. Identity: Botanical and Chemical Names, Natural Source, and Common Forms

1.1 Taxonomy and Nomenclature

Ganoderma lucidum is a highly regarded medicinal fungus belonging to the Basidiomycota class, Polyporaceae family, and Ganoderma genus. Currently, there are approximately 120 recognized species of the Ganoderma genus worldwide. The species most widely sold and studied commercially is referred to as Ganoderma lucidum (Curtis) P. Karst., though important taxonomic caveats apply. Although the name Ganoderma lucidum, a species originally described from England, has been applied to the fungus widely cultivated in China, their identities are not the same, and this study aimed to clarify the identity of this medicinally and economically important fungus. Molecular and morphological research has established that the name "G. lucidum" as used for the Chinese species is erroneous and should be corrected; G. sichuanense is the correct name to use. Globally, the taxonomy of Ganoderma species is chaotic, and the taxon name Ganoderma lucidum has been used for most laccate (shiny) Ganoderma species. Despite this, the designation "Ganoderma lucidum" remains the near-universal convention in research literature, pharmacopeias, and commerce.

The Latin word lucidus means "shiny" or "brilliant" and refers to the varnished appearance of the surface of the mushroom. In China, G. lucidum is called lingzhi, whereas in Japan the name for the Ganodermataceae family is reishi or mannentake.

1.2 Physical Description and Natural Habitat

Ganoderma lucidum is a mushroom belonging to the family Ganodermataceae in the order Aphyllophorales, has a shape of a kidney, a semi-circle or a fan, and is 5 to 20 cm in diameter. It has ring-shaped grooves on the surface of the brown cap and fine wrinkles in the radial direction. It is widely distributed in the temperate regions of the northern hemisphere, and is a year-old mushroom that grows mainly at the root base of deciduous trees or stumps of dead trees from early summer to autumn.

1.3 Common Forms and Preparations

Among cultivated mushrooms, G. lucidum is unique in that its pharmaceutical rather than nutritional value is paramount. A variety of commercial G. lucidum products are available in various forms, such as powders, dietary supplements, and tea. These are produced from different parts of the mushroom, including mycelia, spores, and fruit body. The traditional medicinal part of Ganoderma lucidum is limited to the fruiting body, namely the sporocarp. Ganoderma lucidum spores are microspores that are ejected from the caps at the mature period of Ganoderma lucidum, and have all the genetically active components of Ganoderma lucidum.

The bioactive constituents of G. lucidum are dependent on different conditions, including the origin, classifications, cultivation process, and method of extraction. According to the Chinese Pharmacopoeia (2015 edition), a minimum of 0.90% polysaccharides and 0.50% triterpenoids are contained in the Ganoderma dry fruiting body.

---

2. Traditional and Historical Use

2.1 East Asian Traditions

Ling-zhi is a famous fungus for its medicinal values well documented in the Chinese literature which can be dated back nearly two thousand years to the Shen Nong Materia Medica (102–200 AD). It symbolises happiness, good fortune, good health and even immortality in Chinese traditional culture.

The first book wholly devoted to the description of herbs and their medicinal value was Shen Nong Ben Cao Jing, written in the Eastern Han dynasty of China (25–220 AD). This book is also known as "Classic of the Materia Medica" or "Shen-nong's Herbal Classics." It describes botanical, zoological, and mineral substances, and was composed in the second century under the pseudonym of Shen-nong ("the holy farmer"). In the Pharmacopoeia of the People's Republic of China, the mushroom is reported to have been used for over two millennia.

In Chinese, the name lingzhi represents a combination of spiritual potency and essence of immortality, and is regarded as the "herb of spiritual potency," symbolizing success, well-being, divine power, and longevity. Historically, lingzhi has been viewed as a magic herb as well as an auspicious symbol by the Chinese. It is, therefore, also known as "Ruizhi," "Shenzhi," and "Xiancao," with the meaning of good fortune and mysterious power. Taoism played an important role in promoting Lingzhi for either medical purposes or otherwise.

Ganoderma lucidum (Reishi) mushroom was recorded among 120 prevalent stimulants (Shang pin) in many popular Chinese Materia Medicas (Shen Nung Ben Cao Jing). It is recorded in ancient books such as "Shennong Bencaojing" and "Compendium of Materia Medica" that Ganoderma lucidum has functions such as "enriching the heart-qi" and "acting on heart and nourishing blood," "benefiting the heart and energizing meridians," "relieving uneasiness of mind and body tranquilization," "benefiting pneuma," and "strengthening muscles and bones."

2.2 Traditional Preparations and Purposes

Ganoderma lucidum is a traditional tonic medicine in China, known as the "fairy grass" and "spiritual grass." In traditional use it was associated with effects of tonifying qi and calming the mind, stopping cough and asthma, and was used to treat restlessness, lung deficiency cough and asthma, fatigue and shortness of breath, and lack of appetite. According to the Chinese pharmacopoeia records, Ganoderma invigorates Qi ('life energy' or 'life force' in TCM); tranquilises the mind; and is used for the treatment of insomnia, palpitations, cough, and asthma.

The specific applications and attributed health benefits of lingzhi include control of blood glucose levels, modulation of the immune system, hepatoprotection, and bacteriostasis, among others. The various beliefs regarding the health benefits of G. lucidum are based largely on anecdotal evidence, traditional use, and cultural mores.

2.3 Japanese and Korean Traditions

Species of Ganoderma, commonly called reishi (in Japan) or lingzhi (in China), have been used in traditional medicine for thousands of years, and their use has gained interest from pharmaceutical industries in recent years. The Japanese name reishi (霊芝) translates roughly as "spiritual mushroom" and reflects a cultural significance parallel to the Chinese tradition.

---

3. Key Constituents and Active Compounds

3.1 Primary Bioactive Classes

Different nutrients such as vitamins, lipids, ganoderan, protein, peptides, minerals, amino acids, fatty acids, and phytochemicals like polyphenols, polyhydroxy acids, isoflavonoids, phytoestrogens, terpenoids, carotenoids, glucosinolates, polysaccharides, and enzymes have been reported in G. lucidum. Among these, the two most pharmacologically significant classes are polysaccharides and triterpenoids.

G. lucidum polysaccharides and triterpenoids are considered the most bioactive compounds, with various health advantages and have increased demand in the market. The primary bioactive components include polysaccharides, triterpenoids, peptides/proteins, and sterols, which together account for multifaceted health benefits.

3.2 Polysaccharides

Ganoderma lucidum polysaccharides (GLPs) are one of the main bioactive ingredients and are widely used in traditional Chinese medicine and traditional medicine fields. Several monomers—for instance, galactose, glucose, xylose, mannose, fucose, rhamnose and arabinose—in the composition of G. lucidum polysaccharide have been described as significantly contributing to its antioxidant, immunomodulatory, antitumor, and antibacterial characteristics. It is well known that polysaccharides, particularly D-glucans, can inhibit angiogenesis and also have immunomodulatory effects on tumors.

3.3 Triterpenoids (Ganoderic Acids)

A comprehensive review listed 83 species of Ganoderma lucidum triterpenoids (GLTs). G. lucidum is the only known source of a particular group of triterpenes, also known as ganoderic acids, which have been found to have direct cancer cell cytotoxicity on a wide variety of cancer cell lines, such as murine Lewis lung carcinoma (LLC) and Meth-A, and many of them have been suggested to counter angiogenesis and metastasis. Compounds studied for antidiabetic effects include polysaccharides, triterpenoids (ganoderic acids, ganoderol B), and proteoglycans.

Several hundreds of compounds such as triterpenes, meroterpenoids, nucleosides, alkaloids, and polysaccharides have been isolated and identified from the genus of G. lucidum.

---

4. Mechanisms of Action

4.1 Immunomodulation

Polysaccharides enhance immune function by activating macrophages, natural killer cells, and T cells, thereby promoting phagocytosis and cytokine production. Triterpenoids contribute through anti-inflammatory and antioxidant activities, inhibiting inflammatory mediators and protecting tissues from damage. Ganoderma lucidum also influences immune regulation via key signaling pathways, including NF-κB and MAPK, and supports immune tolerance, potentially reducing the risk of autoimmune diseases. Additionally, it modulates gut microbiota, which further impacts systemic immunity.

4.2 Anti-inflammatory Effects

Studies across macrophage and animal models reported significant anti-inflammatory effects via reduction in pro-inflammatory markers (TNF-α, IL-1β, IL-6), primarily through downregulation of MAPK and TLR-4/NF-κB signaling pathways. Meta-analysis of in vitro data confirmed significant reductions in NO levels (−3.29 [95% CI: −5.21, −1.37]; p = 0.0008), IL-6 (−3.51 [−4.73, −2.29]; p < 0.00001), and TNF-α (−2.20 [−2.93, −1.48]; p < 0.00001). These findings are derived from preclinical (in vitro and animal) studies only.

4.3 Anticancer Mechanisms (Preclinical)

Various chemical compounds from G. lucidum exhibit anticancer properties mainly through diverse mechanisms such as cytotoxic properties, host immunomodulation, metabolizing enzyme induction, and inhibition of the expression of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) in cancer cells. Evidence from in vitro and in vivo studies has demonstrated that GLP possesses potential anticancer activity through immunomodulatory, anti-proliferative, pro-apoptotic, anti-metastatic, and anti-angiogenic effects.

4.4 Hepatoprotective Mechanisms

G. lucidum protects the liver through a broad range of mechanisms that include the modulation of liver Phase I and II enzymes, the suppression of β-glucuronidase, antifibrotic and antiviral actions, the regulation of the production of nitric oxide (NO), the maintenance of hepatocellular calcium homeostasis, immunomodulatory activity, and scavenging of free radicals.

4.5 Antidiabetic Mechanisms

G. lucidum polysaccharides (GLPs) and triterpenoids have been shown to act through distinct mechanisms, such as improving glucose metabolism, modulating the mitogen-activated protein kinase (MAPK) system, inhibiting the nuclear factor-kappa B (NF-κB) pathway, and protecting the pancreatic beta cells. Triterpenes exhibit potential antihypertensive effects through inhibition of ACE activity and reduction of oxidative stress via upregulation of antioxidant enzymes such as superoxide dismutase (SOD) and catalase, thereby contributing to improved lipid profiles and vascular function.

4.6 Limitations in Mechanistic Understanding

Despite the vast array of reported medicinal attributes of Ganoderma, the pathways and mechanisms of action of its bioactive substances remain poorly defined. With further advancement in modern research technologies, clear and detailed insights into these pathways and mechanisms of action are becoming increasingly possible. The structural complexity and isomer diversity of triterpenoid compounds remain significant barriers to pharmacological standardization.

---

5. Scientific Evidence by Area of Use

5.1 Cancer (Adjunct to Conventional Treatment)

Prompted by the promising anticancer potential established by laboratory studies, a few randomised controlled trials (RCTs) have been conducted to evaluate the clinical effectiveness of G. lucidum. However, the majority of clinical trials are conducted in Asia and published in Asian databases. Full-text publications are usually not available in English.

The most authoritative summary of human clinical evidence is a Cochrane systematic review (Jin et al., 2016). There were 5 studies with 373 people who were randomly selected to receive either Ganoderma lucidum or a placebo or other treatment. Although most studies were from 1 to 3 months in duration, the lengths of treatment and specific dosages of Ganoderma lucidum were not clear. The evidence from the studies was of low to very low quality.

A Cochrane meta-analysis showed that patients who had been administered Ganoderma lucidum alongside chemo-/radiotherapy were more likely to respond positively than with chemo-/radiotherapy alone. These trials demonstrated improved immune functions as measured by increased CD3, CD4, and CD8 immune response cells.

Based on the evidence to date, using Ganoderma lucidum for cancer treatment may increase the chance of better response to treatment, but this is uncertain. It may improve the body's immune response, in particular on T-cells, but the effect on natural killer cell (NK) activity is uncertain. It may improve quality of life and it may have little or no effect on adverse events. These studies were all short-term and did not measure survival after cancer, which is an important outcome that should be measured in future research.

It remains uncertain whether G. lucidum helps prolong long-term cancer survival. However, G. lucidum could be administered as an alternative adjunct to conventional treatment in consideration of its potential of enhancing tumour response and stimulating host immunity.

Though numerous clinical trials have been undertaken to determine its effectiveness, there is still not enough evidence to support its use as a first-line treatment for cancer. Published systematic reviews point to the need for improved methodological quality and more clinical research.

Evidence strength: Low to very low quality (Cochrane grading). The evidence base is limited by small trial sizes, methodological weaknesses, predominantly Asian populations, and short follow-up periods with no data on long-term survival.

5.2 Cardiovascular Risk Factors (Blood Glucose, Blood Pressure, Lipids)

Some human studies with intervention lengths of 4–12 weeks in patients with type 2 diabetes mellitus or hypertension have reported improvements in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial glucose, insulin, and C-peptide, total cholesterol, LDL cholesterol, and blood pressure, whilst other studies have reported no changes in glucose parameters, and unchanged LDL cholesterol. However, for all these clinical trials reporting positive results, the reporting of methods was poor and unclear, with a high potential for bias.

A key high-quality RCT (Klupp et al., 2016, published in Scientific Reports) enrolled 84 participants with type 2 diabetes and metabolic syndrome. Eighty-four participants with type 2 diabetes mellitus and metabolic syndrome were randomised to one of three intervention groups: Ganoderma lucidum, Ganoderma lucidum with Cordyceps sinensis, or placebo. The dosage was 3 g/day of Ganoderma lucidum, with or without Cordyceps sinensis, for 16 weeks. The primary outcome measure was blood glucose (HbA1c and fasting plasma glucose). After controlling for baseline differences, combined Ganoderma lucidum did not significantly affect any of the outcome measures (co-primary: HbA1c and FPG; and secondary: blood pressure, triglycerides, waist circumference, BMI, health-related quality of life, C-reactive protein, total, HDL and LDL cholesterol, and apolipoproteins A and B) compared to placebo at 16 weeks.

A Cochrane review on cardiovascular risk factors (Klupp et al., 2015) evaluated five trials with 398 participants. The three studies from which data were used for statistical analyses compared G. lucidum (1.4 g to 3 g per day) to placebo over 12 to 16 weeks of intervention. No improvement was found for fasting plasma glucose (WMD 0.30 mmol/L; 95% CI −0.95 to 1.55 mmol/L). Measures of post-prandial blood glucose found inconsistent results. There were no statistically significant differences between groups for blood pressure or triglycerides. Evidence from a small number of randomised controlled trials does not support the use of G. lucidum for treatment of cardiovascular risk factors in people with type 2 diabetes mellitus.

One smaller clinical trial (26 patients) with a different protocol reported a positive outcome: a clinical trial involving 26 patients with borderline hypertension/hyperlipidemia demonstrated that 12 weeks of supplementation with 1.44 g/day G. lucidum extract significantly increased HDL-cholesterol by 24% and reduced triglycerides by 8%, while also improving insulin resistance.

A GRADE-assessed systematic review and meta-analysis (Jafari et al., 2025) pooling 17 RCTs with 971 participants showed: significant reductions in BMI (WMD = −0.43; 95% CI: −0.77, −0.10; p = 0.011), creatinine (WMD = −0.14; 95% CI: −0.27, −0.02; p = 0.028), glutathione peroxidase (GPx) (WMD = 2.29; 95% CI: 1.67, 2.92; p < 0.001), and heart rate (WMD = −3.92; 95% CI: −7.45, −0.40; p = 0.029). No significant effects were observed on body fat, waist circumference, blood pressure, fasting glucose, lipid profile, inflammatory markers, or liver enzymes. Critically, the GRADE profile for Ganoderma supplementation indicated that the quality of evidence was very low across all outcomes. Ganoderma lucidum supplementation may have modest effects on certain health indices, but the evidence is limited by very low quality.

Evidence strength: Very low quality overall (GRADE). The best-designed trials to date have not demonstrated significant benefit for primary cardiovascular risk factors in metabolic syndrome or type 2 diabetes.

5.3 Immune Function

The immunomodulating effects of G. lucidum are extensive, including promoting the function of antigen-presenting cells, the mononuclear phagocyte system, humoral immunity, and cellular immunity. Preclinical data, including cell culture and animal models, demonstrate that G. lucidum enhances the proliferation and maturation of T and B lymphocytes, splenic mononuclear cells, NK cells and dendritic cells, and has been shown to affect gene expression of IL-1β, IL-6, IL-10, and tumor necrosis factor (TNF)-α. A polysaccharide fraction was shown to enhance both innate and adaptive immunities by triggering the production of cytokines from mouse splenocytes.

In human studies, evidence is primarily derived from cancer trials in which immune markers were a secondary outcome. Polysaccharides and triterpenoids demonstrate promising clinical application prospects in metabolic diseases, inflammatory conditions, neurodegenerative disorders, and cancer immunotherapy, attributed to their multi-target immunomodulatory activities and prebiotic properties. Despite these promising applications, further research is needed to fully elucidate the molecular mechanisms and potential of Ganoderma lucidum in precision medicine.

Evidence strength: Preclinical evidence is robust; direct human evidence specifically for healthy immune function enhancement is limited and requires larger well-controlled trials.

5.4 Liver/Hepatoprotection

G. lucidum exhibits a broad range of hepatoprotective impacts in various liver disorders, such as hepatic cancer, nonalcoholic fatty liver disease (NAFLD), alcohol-induced liver disease, hepatitis B, hepatic fibrosis, and liver injury induced by carbon tetrachloride (CCl4) and α-amanitin. Most of this evidence is from animal models: treatment with the G. lucidum extract reduced elevated ALT, AST, and ALP levels, and cellular oxidative stress markers, and increased endogenous antioxidant levels. Histopathology observations revealed that inflammation, infiltration of immune cells, and aberration of collagen fibers in the hepatocytes were altered. The increased expression of inflammatory cytokines TNF-α, TGF-β, IL-1β, and IL-6 were markedly suppressed.

Human clinical evidence for hepatoprotective effects specifically is sparse. A review of the hepatoprotective activity of mushrooms noted the need for clinical trials in humans with acute liver failure.

Evidence strength: Predominantly animal/in vitro. Clinical human evidence for hepatoprotection is not well established.

5.5 Sleep and Fatigue

Randomised controlled trials for insomnia have shown that Ganoderma can improve sleep quality and reduce the incidences of adverse effects and dependence. In animal studies, Ganoderma extract reduced sleep latency and prolonged sleep duration, which might be related to tumour necrosis factor (TNF) and γ-aminobutyric acid receptor activities.

Evidence strength: Preliminary. Some supportive RCT evidence exists for sleep quality, but the evidence base is small.

5.6 Other Areas Under Investigation

Rigorous investigations have reported that G. lucidum presents a range of pharmacologically active constituents with anticancer, cardioprotective, hepatoprotective, antioxidant, immunomodulatory, antihypertensive, and antidiabetic effects. It is important to note that the majority of research on G. lucidum and diabetes that is currently accessible was done in vitro or on animals. To validate these initial results, longer-term and larger-sample clinical trials are required.

---

6. Body Systems Associated with Ganoderma

• Immune system: Immunomodulation via polysaccharide activation of innate and adaptive immune cells; cytokine regulation.
• Cardiovascular system: Investigated for effects on blood pressure, cholesterol, triglycerides, and platelet aggregation.
• Metabolic/endocrine system: Studied for effects on blood glucose, insulin sensitivity, and metabolic syndrome.
• Hepatic system: Preclinically linked to hepatoprotection from toxic and inflammatory insults.
• Nervous system/sleep: Traditionally used for calming the mind; some RCT data support effects on sleep quality.
• Oncology (adjunct): Studied as an adjuvant to chemo/radiotherapy for immune stimulation and quality of life.
• Gut microbiota: Numerous studies have demonstrated the ability of G. lucidum and its active components to regulate gut flora.

---

7. Dosage Forms and Dosages Reported in Studies

There are no scientific data on a safe and effective dosage of Ganoderma lucidum. The following dosages were used in specific clinical studies:

• Three studies compared G. lucidum at 1.4 g to 3 g per day to placebo over 12 to 16 weeks of intervention.
• The dosage in one double-blind RCT in metabolic syndrome was 3 g/day of Ganoderma lucidum, with or without Cordyceps sinensis, for 16 weeks.
• One trial investigating cardiovascular markers in borderline hypertension/hyperlipidemia used 1.44 g/day G. lucidum extract for 12 weeks.
• In a small trial (N = 16) utilizing 4,000 mg daily of a Ganoderma supplement (containing 1.89% terpenoids and 15.8% polysaccharides) for 10 days in healthy volunteers, there were no adverse effects reported.
• In a small retrospective trial in people with epilepsy (N = 18) taking Ganoderma spore powder 3,000 mg daily for eight weeks, only minor/mild adverse events were observed, including stomach discomfort (22% of participants), nausea (33%), and xerostomia (17%).
• A systematic review assessed supplementation ranging from 200 to 11,200 mg/day over 1–24 weeks.

Many challenges are encountered due to a range of factors from dosage to production quality. Strategies for enhancing quality control procedures to define and standardize G. lucidum preparations are needed to determine mechanisms of action and to help characterize the active component(s) of this putative medicinal mushroom.

---

8. Safety, Adverse Effects, and Drug Interactions

8.1 General Safety Profile

In regards to safety, β-glucan derived from G. lucidum has been designated as "generally recognized as safe" (GRAS) by the U.S. Food and Drug Administration (FDA). Systematic review of Ganoderma spore powder has indicated no serious adverse effects and no abnormalities in hepatic or renal function; gastrointestinal (GI) concerns are among the more commonly reported side effects with Ganoderma supplementation.

G. lucidum was generally well tolerated by most participants in clinical trials, with only a scattered number of minor adverse events. No major toxicity was observed across the studies. In a meta-analysis of five trials with 398 participants with cardiovascular risk factors, there were no abnormalities in hematological, hepatic, or renal safety biomarkers, and no moderate or severe adverse effects reported in trials with doses of G. lucidum ranging from 1,400 to 3,000 mg daily for periods of 12–16 weeks.

8.2 Hepatotoxicity

Despite its broad reputation as hepatoprotective, case reports document hepatotoxic reactions associated with specific formulations. Hepatotoxic effects related to Ganoderma lucidum mushroom powder were first described in a patient from Hong Kong in 2004. In 2005, a case of fatal fulminant hepatitis associated with such a preparation was reported. Both patients had taken other therapeutic agents and traditionally boiled Lingzhi without any toxic effect. After switching to taking Lingzhi in powder form for 1–2 months, the hepatotoxic episode occurred in both patients. The toxic role of Lingzhi powder needs close monitoring in the future, especially in combination with other drugs.

How herb-induced liver injury (HILI) behaves is more varied owing to the inconsistent dosage, formulation, and possible contamination during preparation, manufacturing, production, and storage. Given the rarity of overt adverse events, idiosyncratic reactions are a plausible mechanism.

8.3 Anticoagulant Interactions

Ganoderma lucidum can compromise hemostasis because of its antithrombotic and anticoagulant activity. A case report documented a clinically significant drug interaction: a patient on hemodialysis with ongoing anticoagulant therapy with warfarin showed two consecutive markedly increased INR values (6.92 and 8.22), confirmed by two different instruments. Anamnesis revealed a recent ingestion of two 500 mg tablets of Ganoderma lucidum extract on both occasions. A systematic review identified and reported on the potential risk of interaction between warfarin and Ganoderma lucidum.

8.4 CYP450 Enzyme Interactions

Studies have examined the effect of G. lucidum on CYP metabolic function. Researchers systematically studied the inhibition of G. lucidum on various subtypes of the CYP enzymes, clarified the main active substances of G. lucidum that interact with CYP enzymes and their impact on clinical drug metabolism, providing a reference for the rational use of G. lucidum. The clinical significance of these in vitro findings for humans taking standard pharmaceutical drugs requires further investigation.

8.5 Adverse Events in Controlled Trials

Participants who took G. lucidum for four months were 1.67 times (RR 1.67, 95% CI 0.86 to 3.24) more likely to experience an adverse event than those who took placebo, but these were not serious side effects. The most commonly reported adverse events in published trials are gastrointestinal in nature.

8.6 Standardization and Product Quality Concerns

It is likely that differences in the quality and quantity of medicinally relevant chemicals occur among Ganoderma species. Human experimental studies have often been small, and the results are not always supportive of the in vitro findings. The great wealth of chemical data and anecdotal evidence on the effects of G. lucidum needs to be complemented by reliable experimental and clinical data from well-designed human trials to clearly establish if the reported health-related effects are valid and significant.

G. lucidum remains an underexplored resource in modern nutraceutical and pharmaceutical research. Notably, few bioactive compounds derived from this mushroom have been clinically validated as superior to existing therapies for disease treatment.

References

• Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoderma lucidum (Lingzhi or Reishi) — Herbal Medicine: Biomolecular and Clinical Aspects (NCBI Bookshelf, NIH)
• Wang XC et al. The Species Identity of the Widely Cultivated Ganoderma, 'G. lucidum' (Ling-zhi), in China. PLOS ONE, 2012.
• Wang XC et al. The Species Identity of the Widely Cultivated Ganoderma, 'G. lucidum' (Ling-zhi), in China. PMC, 2012.
• Jin X et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews, 2019 (PMC).
• Jin X, Ruiz Beguerie J, Sze DM, Chan GCF. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Library, 2016.
• Jin X et al. A Summary of a Cochrane Review: Ganoderma lucidum (Reishi mushroom) for the treatment of cancer. PMC, 2017.
• Klupp NL et al. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Scientific Reports, 2016 (PMC).
• Klupp NL et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors (Cochrane review). PubMed, 2015.
• Jafari M et al. The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials. Food Science & Nutrition, 2025 (PMC).
• Hassan M et al. Ganoderma lucidum: Novel Insight into Hepatoprotective Potential with Mechanisms of Action. PMC, 2023.
• Immunomodulatory Effects of Ganoderma lucidum Bioactive Compounds on Gut–Brain and Gut–Liver Axis Disorders. PMC, 2025.
• A Review of Bioactive Components and Pharmacological Effects of Ganoderma lucidum. PMC, 2025.
• Exploration of the anti-insomnia mechanism of Ganoderma by central-peripheral multi-level interaction network analysis. PMC, 2021.
• Lingzhi, Reishi — LiverTox. NCBI Bookshelf / NIH.
• Wanmuang H et al. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai, 2007. ResearchGate.
• Yuen MF et al. Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). Journal of Hepatology, 2004.
• Manno ML, Montinaro AM. Suspected interaction of Ganoderma lucidum on warfarin therapy in hemodialysis patient. La Rivista Italiana della Medicina di Laboratorio, 2020.
• Tan SL et al. Warfarin and food, herbal or dietary supplement interactions: A systematic review. British Journal of Clinical Pharmacology, 2021.
• Triterpenoids from Ganoderma lucidum inhibit cytochrome P450 enzymes interfering with the metabolic process of specific clinical drugs. PMC, 2024.
• Ganoderma lucidum polysaccharides as an anti-cancer agent. PMC, 2019.
• Amelioration of CCl4-induced oxidative stress and hepatotoxicity by Ganoderma lucidum in Long Evans rats. PMC, 2023.
• Exploring the Therapeutic Potential of Ganoderma lucidum in Cancer. PMC, 2024.
• Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence. PMC, 2025.
• Multifaceted mechanisms to combat diabetes through polysaccharides and triterpenoids: A comprehensive review. ScienceDirect, 2024.
• Klupp NL et al. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for metabolic syndrome. Scientific Reports, 2016 (Nature).
• Health benefits of Ganoderma lucidum polysaccharides: A review of potential cardiovascular protective effects. ScienceDirect, 2025.
• Development of Ling-zhi industry in China – emanated from artificial cultivation in the Institute of Microbiology, Chinese Academy of Sciences (IMCAS). PMC, 2018.
• Lucius K. Clinical Evidence for the Use of Ganoderma lucidum Medicinal Mushroom. Integrative Cancer Therapies, 2025.
• Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa. Frontiers in Pharmacology, 2022.